fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

FDA grants priority review to Keytruda in Hodgkin lymphoma.- Merck Inc

Written by | 10 Jul 2020 | Pharmacy

Merck Inc announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab), as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

This sBLA is based on data from the pivotal Phase III KEYNOTE-204 trial, in which Keytruda demonstrated a significant improvement in progression-free survival (PFS) compared to brentuximab vedotin (BV), a current standard of care in this patient population. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of Oct. 30, 2020.

KEYNOTE-204 also serves as the confirmatory trial for the Keytruda accelerated approval hematology indications. Data from KEYNOTE-204 were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.